The VALCAN-O score, which uses a data set from the VHA, was developed for patients diagnosed with resectable early-stage nonsmall-cell lung cancer (NSCLC).
Walter Reed, NIAID Scientists Help Develop Monoclonal Antibodies That Might Block Epstein-Barr Virus Infection; EBV Linked to MS Development
Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and Walter Reed Army Institute of Research (WRAIR) have developed a panel of investigational monoclonal antibodies (mAbs) that target two key proteins—gH and gL—on the surface of the Epstein-Barr virus (EBV).
Large VA Study Finds Lower Prostate Cancer Screening Rates Associated With Subsequent Increases in Metastatic Cancer
Aside from skin cancer, prostate cancer is the most common cancer among male veterans. When diagnosed at an early stage, prostate cancer is highly curable.
Achieving Treatment-Free Remission in CML: Best Approaches, Best Candidates
In less than two decades, the advent of targeted therapies transformed chronic myeloid leukemia (CML) from a death sentence with a five-year survival rate of just 22% to a chronic condition with five-year survival exceeding 90%.
VA Frailty Index Associated With Survival in AML Patients
Acute myeloid leukemia (AML) is a particularly aggressive blood cancer that is most successfully treated with intensive chemotherapy. As the average age at diagnosis is 68, patients diagnosed with the disease are often too frail to withstand potentially curative treatment with induction regimens.
New BTK Inhibitor Extends Progression-Free Survival in CLL
A late-breaking presentation at the 64th American Society of Hematology Annual Meeting in New Orleans on Dec. 13 demonstrated that zanubrutinib outperformed ibrutinib in terms of both objective response rate and progression-free survival for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Is It Time to Rethink Stem Cell Transplantation in Young Patients With MM?
BETHESDA, MD—Multiple myeloma (MM) is primarily a disease of the elderly, with an average age at diagnosis of 68. Still, adolescents and young adults (AYAs) do develop the blood disease and represent about 5% of all new cases. Because MM is so uncommon in younger age...
The Role of Cardiac Screening for CLL Patients on Ibrutinib
Ibrutinib transformed treatment for chronic lymphocytic leukemia (CLL) when introduced in 2014. While it continues to be widely used, the Bruton’s tyrosine kinase (BTK) inhibitor is associated with a significant risk of cardiac adverse events, particularly cardiac arrhythmias.
Improving a Risk Model for VTE in Lung Cancer Patients Receiving ICI
The St. Louis VA investigators and colleagues at the Fred Hutchison Cancer Institute in Seattle sought to identify specific risk factors that predispose patients to ICI-associated VTE and could be used to stratify outpatients with non-small cell lung cancer (NSCLC) for thromboprophylaxis.
Increased Risk of COVID-19 Breakthrough Persists in MM Patients After Boosting
BOSTON—Since early in the COVID-19 pandemic, physicians have been aware of the greater risk posed by the SARS-CoV-2 virus to patients with compromised immune systems. Among patients with multiple myeloma (MM), more than 30% died of the virus in early waves before the...
Novel Agents Supplant Chemotherapy as 1L CLL Therapy in VA
For years, chemotherapy provided the only hope for patients with chronic lymphocytic leukemia (CLL).
VA Researchers Illuminate a New Blood Cancer, a Novel Type of CLL
In the case of chronic lymphocytic leukemia (CLL) with prolymphocytic progression, a newly defined and very rare type of cancer, the scale of the VA and the number of patients it treats with leukemia allowed VA researchers to describe the characteristics and progression of the disease and begin to understand how it responds to current therapies.
Adjuvant Chemotherapy for All Stage II or III NSCLC? VA Study Urges Caution
Patients with non-metastatic non-small cell lung cancer (NSCLC) face a substantial risk of recurrence and death from the disease even after potentially curative surgical resection.
Recommendations Could Standardize Care for VA Patients With AML, CLL
The VA has committed to providing quality oncology care, with the establishment of the National Oncology Program and a system of excellence designed to spread best practices in cancer care to VA facilities around the country.
VA Research Provides Insight into Quality of Life After Blood, Marrow Transplant
Patients with acute myeloid leukemia (AML) face difficult choices if their cancer recurs. Without treatment, survival is a matter of months.
Achieving Treatment-Free Remission in CML: Best Approaches, Best Candidates
In less than two decades, the advent of targeted therapies transformed chronic myeloid leukemia (CML) from a death sentence with a five-year survival rate of just 22% to a chronic condition with five-year survival exceeding 90%.
VA Researchers Develop AI-based Tool to Predict Post-transplant Relapse in AML
Despite advances in treatment, acute myeloid leukemia (AML) remains the most deadly blood malignancy, with a five-year survival rate of 26% for people over age 20.
Matched Siblings Are the Optimal Allo-HCT Donors for MDS Patients
Myelodysplastic syndromes (MDS), a condition linked to contaminated water at Camp Lejeune for some veterans, are the second common indication for an allogeneic hematopoietic stem cell transplant (Allo-HCT.)
Black MDS Patients Appear to Have Better Overall Survival Than Whites
Certain veterans who were stationed at Camp Lejeune, NC, between Aug. 1, 1953, and Dec. 31, 1987, have a presumptive service connection to aplastic anemia and other myelodysplastic syndromes because of exposure to contaminated water.
For the Sixth Year, MDS World Awareness Day Coming Up This Month
The annual MDS World Awareness Day is designed to raise awareness of myelodysplastic syndromes. The rare group of blood cancers occurs when the blood-forming cells in the bone marrow become abnormal.
New Center at NYU Will Focus on How Social Factors Might Affect Veterans Using Telehealth for Cancer
As part of a larger initiative, a center will be established at New York University to determine how social factors might affect the delivery of telehealth for cancer care.
VA Researchers Suggest Non-Hispanic Black Men Might Need More Frequent PSA Screening to Reduce Risk of Prostate Cancer-Specific Mortality
The benefits of annual prostate-specific antigen screening (PSA) appear to vary by race, decreasing the risk of prostate cancer-specific mortality among non-Hispanic Black men but not non-Hispanic white men, according to a new veteran study.
Pediatric ALL Survivors Have High Follow-Up Screening Rates in MHS
Does universal access to healthcare make any difference in health screening for pediatric acute lymphoblastic leukemia (ALL) survivors?
SBRT Linked to Less Toxicity Than Limited Resection But More Fatigue
NEW YORK – For the estimated one-fourth of early-stage lung cancer patients not medically fit for lobectomy, limited resection and stereotactic body radiation therapy (SBRT) are seen as alternative treatments. “Given the equipoise on the effectiveness of the two...
Should USPSTF Lung Cancer Screening Recommendations Be Expanded?
WASHINGTON, DC – In 2021, the U.S. Preventive Services Task Force recommended annual lung cancer screening with low-dose computed tomography (LDCT) for adults aged 50 to 80 years who have a 20-pack-year smoking history and currently smoke or have quit within the past...
Biomarkers Can Stratify outcomes in Some ICI-Treated NSCLC Patients
NEW HAVEN, CT – In non-small cell lung cancer (NSCLC), there are limited predictive biomarkers for anticancer immunotherapy. Proposed as candidate biomarkers for immune checkpoint inhibitors (ICI) in patients with advanced NSCLC are tumor-infiltrating lymphocytes...
Veterans With CLL/SLL Have Suboptimal Adherence to New Therapies
Suboptimal adherence to new therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), as well as related costs and healthcare resource use, demonstrate unmet needs in real-world treatment of the blood cancers, according to a new review.
Comorbidities Affect When Adjuvant Chemotherapy Is Optimal in NSCLC
While veterans with locoregional non-small cell lung cancer (NSCLC) might find adjuvant chemotherapy beneficial, the risks might outweigh the benefit for some of them.
Survival Affected by Lack of Equitable Access to Pre-Operative NSCLC Care
The VHA appears to fall short in providing equitable access to pre-operative care, which is associated with worse short- and long-term outcomes in clinical stage I non-small-cell lung cancer (NSCLC), according to a recent report.
VA Frailty Index Identifies Older NSCLC Patients at High Risk
The VA’s Frailty Index (VA-FI) was created to identify patients at high risk of unfavorable outcomes. A new study sought to determine how it works with older patients with non-small cell lung cancer (NSCLC).
